Review Article

Overview of non-innovator biological products in India


Abstract: As per regulatory requirements, biosimilar drugs must show high similarity to their reference product in both pre-clinical and clinical tests. It is by these means that biosimilars are considered… Read More »

The Evolution of the European Biosimilars Market

Author(s): ,

Abstract: Biosimilars are follow-on biologics which can be introduced in the market after patents of the originator biologic medicine (reference product) have expired. Contrary to small molecule generics where the… Read More »

Page 5 of 5 « Previous1 2 3 4 5
Go Back Print